FY 2021 VA-Funded Projects
sputnik 5 vaccine :: Article Creator Early Data Shows Russia's Sputnik V COVID-19 Vaccine Produces Immune Response A trial of Russia's Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. Preliminary results published in The Lancet are from a non-randomised phase 1/2 trial of 76 people aged 18-60, which found an antibody response within 21 days and no serious adverse events after 42 days. The vaccine also produced a T-cell response within 28 days, a secondary outcome. And although there were no serious adverse events detected in the two formulations, the small sample size means that it's impossible to draw conclusions about its safety until data from a larger trial are available. The World Health Organization has placed the vaccine in third place on its list of 34 coronavirus vaccines in clinical trials, and the vaccine...